Doxorubicin treatment increases metastasis of prostate tumor (R3327-MatLyLu)

A. A. Geldof, B. R. Rao

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Doxorubicin (Dx) effects on metastatic spreading of prostate cancer were investigated using a rat metastatic tumor (R3327-MatLyLu). Intravenous injection of monodispersed tumor cells resulted in tumor nodule formation in the lungs. A simultaneous bolus injection of Dx (3.2 mg/Kg) caused a significant decrease in lung colony formation and growth. However, Dx administered during the course of spontaneous metastasis, or as adjuvant chemotherapy 24 hours before surgical removal of primary tumor, caused a significant increase in metastasis to the lungs. It is concluded that an intravenous doxorubicin bolus injection does not provide an antimetastatic effect, but increases metastastic spreading of prostate tumor.

Original languageEnglish
Pages (from-to)1335-1339
Number of pages5
JournalAnticancer Research
Volume8
Issue number6
Publication statusPublished - 1 Dec 1988

Cite this

@article{a8fd84ca99ba43f38dae1a5fc521a205,
title = "Doxorubicin treatment increases metastasis of prostate tumor (R3327-MatLyLu)",
abstract = "Doxorubicin (Dx) effects on metastatic spreading of prostate cancer were investigated using a rat metastatic tumor (R3327-MatLyLu). Intravenous injection of monodispersed tumor cells resulted in tumor nodule formation in the lungs. A simultaneous bolus injection of Dx (3.2 mg/Kg) caused a significant decrease in lung colony formation and growth. However, Dx administered during the course of spontaneous metastasis, or as adjuvant chemotherapy 24 hours before surgical removal of primary tumor, caused a significant increase in metastasis to the lungs. It is concluded that an intravenous doxorubicin bolus injection does not provide an antimetastatic effect, but increases metastastic spreading of prostate tumor.",
author = "Geldof, {A. A.} and Rao, {B. R.}",
year = "1988",
month = "12",
day = "1",
language = "English",
volume = "8",
pages = "1335--1339",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

Doxorubicin treatment increases metastasis of prostate tumor (R3327-MatLyLu). / Geldof, A. A.; Rao, B. R.

In: Anticancer Research, Vol. 8, No. 6, 01.12.1988, p. 1335-1339.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Doxorubicin treatment increases metastasis of prostate tumor (R3327-MatLyLu)

AU - Geldof, A. A.

AU - Rao, B. R.

PY - 1988/12/1

Y1 - 1988/12/1

N2 - Doxorubicin (Dx) effects on metastatic spreading of prostate cancer were investigated using a rat metastatic tumor (R3327-MatLyLu). Intravenous injection of monodispersed tumor cells resulted in tumor nodule formation in the lungs. A simultaneous bolus injection of Dx (3.2 mg/Kg) caused a significant decrease in lung colony formation and growth. However, Dx administered during the course of spontaneous metastasis, or as adjuvant chemotherapy 24 hours before surgical removal of primary tumor, caused a significant increase in metastasis to the lungs. It is concluded that an intravenous doxorubicin bolus injection does not provide an antimetastatic effect, but increases metastastic spreading of prostate tumor.

AB - Doxorubicin (Dx) effects on metastatic spreading of prostate cancer were investigated using a rat metastatic tumor (R3327-MatLyLu). Intravenous injection of monodispersed tumor cells resulted in tumor nodule formation in the lungs. A simultaneous bolus injection of Dx (3.2 mg/Kg) caused a significant decrease in lung colony formation and growth. However, Dx administered during the course of spontaneous metastasis, or as adjuvant chemotherapy 24 hours before surgical removal of primary tumor, caused a significant increase in metastasis to the lungs. It is concluded that an intravenous doxorubicin bolus injection does not provide an antimetastatic effect, but increases metastastic spreading of prostate tumor.

UR - http://www.scopus.com/inward/record.url?scp=0024202196&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 1335

EP - 1339

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -